The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Gene: NLRX1
UniProt Accession: Q86UT6
Synonyms: NOD5, NOD9, CLR11.3
Organism: Homo sapiens (Human)
Protein Family: NLRP family (NLR superfamily)
NLRX1 (NLR family member X1) is a unique member of the nucleotide-binding domain and leucine-rich repeat (NLR) protein family that distinguishes itself from other NLRs through its mitochondrial localization (bi2024nlrx1versatilefunctions pages 1-2, pickering2021nlrinexile pages 1-4). Unlike typical NLRs that function in the cytoplasm, NLRX1 is the only NLR family member to localize to mitochondria, making it an atypical pattern recognition receptor with specialized regulatory functions (bi2024nlrx1versatilefunctions pages 1-2, pickering2021nlrinexile pages 1-4, chou2023thenlrgene pages 1-3). The protein belongs to the NLRP family and contains characteristic domains including a central NACHT (nucleotide-binding and oligomerization) domain, C-terminal leucine-rich repeats (LRR), and a unique N-terminal region housing a mitochondrial targeting sequence (bi2024nlrx1versatilefunctions pages 1-2, pickering2021nlrinexile pages 1-4, fekete2021focusingonthe pages 1-2).
NLRX1 possesses a modular domain organization consisting of three main regions (pickering2021nlrinexile pages 1-4, chou2023thenlrgene pages 1-3):
N-terminal region (amino acids 1-39): Contains a functional mitochondrial targeting sequence (MTS) that directs the nascent protein to mitochondria. This sequence is cleaved by mitochondrial matrix proteases upon import, yielding the mature protein (bi2024nlrx1versatilefunctions pages 1-2, bi2024nlrx1versatilefunctions pages 2-3).
NACHT domain (central region): This nucleotide-binding and oligomerization domain is responsible for ATPase activity and protein-protein interactions. Recent structural studies using AlphaFold2 modeling have revealed that NLRX1 can form stable centrosymmetric hexameric structures, a characteristic feature of AAA+ (ATPase Associated with Diverse Cellular Activity) family proteins (jewell2024insightsintothe pages 1-2).
Leucine-rich repeat (LRR) domain (C-terminal, residues 629-975): The LRR domain has been crystallized (PDB: 3UN9) and serves multiple functions including ligand binding, protein interactions, and metabolite sensing. Recent breakthrough studies identified binding pockets for RNA and acetyl-coenzyme A (AcCoA) within the LRR domain, revealing novel regulatory mechanisms (jewell2024insightsintothe pages 1-2, zhang2026cytosolicacetylcoenzymea pages 1-2).
Advanced structural analyses published in 2024 demonstrate that the LRR domain maintains NLRX1 in an autoinhibited state through interactions with the NACHT domain. Binding of cytosolic AcCoA to a conserved pocket on the LRR domain enhances this interaction, preventing NLRX1 from associating with LC3 and thus regulating mitophagy initiation (zhang2026cytosolicacetylcoenzymea pages 1-2). This represents an elegant metabolic sensing mechanism linking cellular energy status to mitochondrial quality control.
NLRX1 executes its diverse functions from multiple locations within mitochondria:
Mitochondrial Matrix: Following import through the TOM (translocase of outer membrane) and TIM (translocase of inner membrane) complexes, mature NLRX1 localizes to the mitochondrial matrix where it interacts with UQCRC2, a matrix-facing component of respiratory chain complex III (bi2024nlrx1versatilefunctions pages 1-2, bi2024nlrx1versatilefunctions pages 2-3). In this location, NLRX1 influences reactive oxygen species (ROS) generation and mitochondrial metabolism.
Inner Mitochondrial Membrane: Groundbreaking research published in 2025 definitively localized NLRX1 to the inner mitochondrial membrane using mitochondrial sub-fractionation studies (xiao2025theinnateimmune pages 2-5, xiao2025theinnateimmune pages 5-7). At this location, NLRX1 plays a critical role in regulating the mitochondrial permeability transition pore (mPTP), demonstrating that NLRX1 is required for calcium-induced mPTP opening (xiao2025theinnateimmune pages 5-7).
Outer Mitochondrial Membrane: Recent evidence also places NLRX1 on the outer mitochondrial membrane, particularly in its capacity as a mitophagy receptor. In this location, NLRX1 can directly interact with cytosolic LC3 to initiate selective mitochondrial autophagy (bi2024nlrx1versatilefunctions pages 1-2, zhang2026cytosolicacetylcoenzymea pages 1-2).
This dynamic multi-compartmental localization enables NLRX1 to integrate signals from different mitochondrial microenvironments and coordinate complex cellular responses.
A central and increasingly recognized function of NLRX1 is its role as a mitophagy receptor that mediates selective removal of damaged mitochondria (bi2024nlrx1versatilefunctions pages 1-2, zhang2026cytosolicacetylcoenzymea pages 1-2). NLRX1 directly binds to LC3 (microtubule-associated protein 1 light chain 3), the key autophagosome marker, to facilitate mitochondrial engulfment. This function has been demonstrated across multiple tissue types and disease models, with 2024 studies proposing that mitophagy regulation may represent the overarching unifying function of NLRX1 (bi2024nlrx1versatilefunctions pages 1-2).
Mechanism: NLRX1 detects mitochondrial protein import stress (MPIS) as a "danger signal" indicating mitochondrial dysfunction. Upon sensing MPIS, NLRX1 promotes LC3 lipidation and recruitment to mitochondria, initiating the mitophagic cascade (bi2024nlrx1versatilefunctions pages 1-2). Recent work in 2026 revealed that cytosolic acetyl-CoA acts as a signaling metabolite: when AcCoA levels decrease (as during fasting), NLRX1's autoinhibition is relieved, allowing LC3 binding and mitophagy induction (zhang2026cytosolicacetylcoenzymea pages 1-2).
NLRX1 functions as a negative regulator of multiple innate immune pathways, dampening inflammatory and antiviral responses:
RIG-I/MAVS Pathway: NLRX1 was initially characterized for its interaction with MAVS (mitochondrial antiviral signaling protein), an adaptor for RIG-I-like receptors (RLRs) that detect viral RNA. NLRX1 sequesters MAVS and prevents RIG-I/MAVS association, thereby reducing type I interferon and NF-κB responses to RNA viruses (bi2024nlrx1versatilefunctions pages 2-3). NLRX1 also activates poly(rC) binding protein 2 (PCBP2) to facilitate proteasomal degradation of MAVS, further suppressing antiviral signaling (bi2024nlrx1versatilefunctions pages 2-3). However, recent literature notes context-dependent effects, with some studies showing that NLRX1 effects on antiviral immunity vary by cell type and specific pathogen (bi2024nlrx1versatilefunctions pages 1-2, pickering2021nlrinexile pages 1-4).
cGAS-STING Pathway: Similar to its effects on MAVS, NLRX1 has been proposed to inhibit the cGAS-STING DNA sensing pathway by preventing STING-TBK1 association, thus limiting type I interferon production in response to cytosolic DNA or mitochondrial DNA (mtDNA) leakage (bi2024nlrx1versatilefunctions pages 2-3, pickering2021nlrinexile pages 1-4).
NF-κB Signaling: NLRX1 negatively regulates NF-κB activation through multiple mechanisms, including binding to TRAF6 (tumor necrosis factor receptor-associated factor 6) to prevent downstream TLR signaling, and interacting with IKK (IκB kinase) to prevent IκB phosphorylation (jewell2024insightsintothe pages 1-2, bi2024nlrx1versatilefunctions pages 2-3). This positions NLRX1 as a key suppressor of inflammatory gene transcription.
NLRX1 plays multifaceted roles in cellular metabolism, functioning as a metabolic checkpoint that coordinates energy production with cellular homeostasis:
OXPHOS Regulation: Through its interaction with FASTKD5 (Fas-activated serine-threonine kinase family protein-5) in the mitochondrial matrix, NLRX1 regulates mitochondrial transcript processing, respiratory complex expression, and oxidative phosphorylation (OXPHOS) activity (chou2022impactofintracellular pages 7-8). The NLRX1-FASTKD5 complex modulates complexes I and IV of the electron transport chain and influences mitochondrial ribosome biogenesis (chou2022impactofintracellular pages 7-8). In human CD4+ T cells infected with HIV-1, this interaction enhances OXPHOS to support viral replication, demonstrating clinically relevant metabolic control (chou2022impactofintracellular pages 7-8).
Glycolysis and Fatty Acid Metabolism: NLRX1 deficiency leads to altered metabolic programming. Studies show that Nlrx1−/− mice are protected against high-fat diet-induced metabolic syndrome and nonalcoholic fatty liver disease (NAFLD), with increased fatty acid oxidation (FAO) and decreased hepatic steatosis (chou2022impactofintracellular pages 7-8). NLRX1 normally restricts mitochondrial fatty acid-dependent OXPHOS while enhancing glycolysis in hepatocytes (chou2022impactofintracellular pages 7-8).
mTOR/AMPK Balance: NLRX1 intersects with major metabolic signaling pathways. In cardiac ischemia-reperfusion models, NLRX1 facilitates mTOR and RISK (reperfusion injury salvage kinase) pathway activation, including phosphorylation of Akt, ERK, and S6K (xiao2025theinnateimmune pages 5-7). NLRX1 deletion is associated with compensatory AMPK activation, linking NLRX1 to the cellular energy-sensing machinery (xiao2025theinnateimmune pages 5-7, chou2022impactofintracellular pages 7-8).
Beyond mitophagy, NLRX1 orchestrates mitochondrial dynamics through novel mechanisms:
NLRX1-SLC39A7 Complex: A 2024 study revealed that NLRX1 forms a complex with the zinc transporter SLC39A7 (ZIP7) on mitochondrial membranes to modulate mitochondrial Zn²⁺ trafficking (song2024thenlrx1slc39a7complex pages 1-2). This complex coordinates mitochondrial fission (via DNM1L/DRP1 phosphorylation and OMA1 activity) with fusion (via L-OPA1:S-OPA1 ratio) and synchronizes these dynamic processes with mitophagy activity. Loss of NLRX1 causes mitochondrial fragmentation and triggers excessive compensatory PINK1-PRKN-mediated mitophagy, leading to cellular senescence (song2024thenlrx1slc39a7complex pages 1-2).
mPTP Regulation: Groundbreaking 2025 research established NLRX1 as a novel required modulator of mPTP opening (xiao2025theinnateimmune pages 2-5, xiao2025theinnateimmune pages 5-7). Using calcium retention capacity assays and mitochondrial sub-fractionation, investigators showed that NLRX1 deletion completely abolished calcium-induced mPTP opening and altered mitochondrial calcium handling. This function links NLRX1 to cardioprotection during ischemia-reperfusion injury (xiao2025theinnateimmune pages 5-7).
NLRX1 participates in multiple interconnected signaling networks. A comprehensive summary is provided in the following table:
| Pathway/Process | Molecular Partners/Targets | Mechanism of Action | Functional Outcome |
|---|---|---|---|
| RIG-I/MAVS antiviral signaling | MAVS, RIG-I, MDA5, PCBP2 | NLRX1 has been reported to associate with MAVS and interfere with RIG-I/MAVS complex formation; it can also promote PCBP2-dependent proteasomal degradation of MAVS. These effects generally dampen downstream IRF3/NF-κB signaling, although some studies note context- and cell-type-dependent disagreement. (bi2024nlrx1versatilefunctions pages 2-3, pickering2021nlrinexile pages 1-4) | Usually decreases type I interferon and antiviral inflammatory responses to RNA viruses; function appears context dependent rather than universally inhibitory. (bi2024nlrx1versatilefunctions pages 2-3, pickering2021nlrinexile pages 1-4) |
| cGAS-STING DNA sensing | STING, TBK1, cGAS | NLRX1 has been proposed to sequester STING or limit STING-TBK1 association, analogous to its reported effects on MAVS-dependent signaling; recent injury and viral-infection literature continues to place NLRX1 upstream of cGAS-STING regulation. (bi2024nlrx1versatilefunctions pages 2-3, pickering2021nlrinexile pages 1-4) | Typically restrains type I interferon production and inflammatory signaling in response to cytosolic DNA or mtDNA leakage. (bi2024nlrx1versatilefunctions pages 2-3, pickering2021nlrinexile pages 1-4) |
| NF-κB inflammation | TRAF6, IKK, IκB, NF-κB | Structural/drug-discovery work and prior functional studies indicate that NLRX1 negatively regulates NF-κB signaling, including through interactions that prevent IKK-mediated IκB phosphorylation and through TRAF6-associated suppression of inflammatory signaling. (jewell2024insightsintothe pages 1-2, bi2024nlrx1versatilefunctions pages 2-3) | Reduced transcription of pro-inflammatory genes and dampened inflammatory signaling; relevant to inflammatory disease targeting. (jewell2024insightsintothe pages 1-2, pickering2021nlrinexile pages 1-4) |
| mTOR/AMPK metabolism | mTOR, RISK kinases (Akt, ERK, S6K), AMPK | NLRX1 influences the balance between anabolic and stress-response signaling. In cardiac ischemia-reperfusion models, NLRX1 supports mTOR and RISK pathway activation, while NLRX1 deficiency is associated with compensatory AMPK activation; other immunometabolic studies link NLRX1 to altered OXPHOS/glycolysis and fatty acid metabolism. (xiao2025theinnateimmune pages 5-7, chou2022impactofintracellular pages 7-8) | Coordinates metabolic adaptation, stress responses, and tissue protection; effects are tissue-specific and can alter susceptibility to ischemic or inflammatory injury. (xiao2025theinnateimmune pages 5-7, chou2022impactofintracellular pages 7-8) |
| Mitophagy receptor function | LC3, LC3 lipidation machinery, mitochondrial import-stress signals | Recent work positions NLRX1 as a mitophagy regulator/receptor. It promotes selective mitochondrial clearance by engaging LC3-related autophagy machinery, and broader literature frames mitophagy control as a core unifying NLRX1 function. (bi2024nlrx1versatilefunctions pages 1-2, zhang2026cytosolicacetylcoenzymea pages 1-2) | Maintains mitochondrial quality control by promoting removal of damaged mitochondria, thereby limiting secondary inflammatory and metabolic dysfunction. (bi2024nlrx1versatilefunctions pages 1-2, zhang2026cytosolicacetylcoenzymea pages 1-2) |
| Mitochondrial dynamics / Zn2+ trafficking | SLC39A7/ZIP7, DNM1L/DRP1, OPA1, OMA1, PINK1-PRKN | In nucleus pulposus cells, NLRX1 forms an NLRX1-SLC39A7 complex on mitochondrial membranes and regulates mitochondrial Zn2+ trafficking, coordinating fission/fusion factors with mitophagy. Loss of NLRX1 causes mitochondrial collapse and compensatory PINK1-PRKN pathway activation. (song2024thenlrx1slc39a7complex pages 1-2) | Preserves balanced mitochondrial dynamics and beneficial mitophagy, preventing senescence-associated mitochondrial failure and inflammatory degeneration. (song2024thenlrx1slc39a7complex pages 1-2) |
| OXPHOS regulation / mitochondrial gene expression | FASTKD5, mitochondrial RNA granules, respiratory complexes I and IV, UQCRC2 | NLRX1 associates with FASTKD5 in the mitochondrial matrix, influencing mitochondrial transcript processing, respiratory-complex expression, ribosome biogenesis/translation, and OXPHOS output. NLRX1 also interacts with UQCRC2, linking it to respiratory-chain function and ROS regulation. (chou2022impactofintracellular pages 7-8, bi2024nlrx1versatilefunctions pages 2-3) | Alters oxidative phosphorylation, glycolysis coupling, and mitochondrial bioenergetics in immune and nonimmune cells; can support virus-associated or tissue-specific metabolic programs. (chou2022impactofintracellular pages 7-8, bi2024nlrx1versatilefunctions pages 2-3) |
| mPTP regulation | mPTP, mitochondrial calcium handling machinery, phosphoproteins in inner mitochondrial membrane | In a 2025 cardiac study, NLRX1 was localized to the inner mitochondrial membrane and found to be required for calcium-induced mPTP opening; deletion abolished mPTP opening and altered mitochondrial calcium retention and phosphoprotein states. (xiao2025theinnateimmune pages 2-5, xiao2025theinnateimmune pages 5-7) | NLRX1 modulates mitochondrial permeability transition and cardioprotective signaling during ischemia-reperfusion, linking innate immune sensing to acute mitochondrial stress responses. (xiao2025theinnateimmune pages 2-5, xiao2025theinnateimmune pages 5-7) |
Table: This table summarizes the main signaling pathways and biochemical functions currently attributed to human NLRX1 from recent and foundational literature. It is useful for functional annotation because it links each pathway to specific molecular partners, mechanistic evidence, and biological outcomes.
The pathways detailed above demonstrate NLRX1's role as a central regulatory hub that integrates mitochondrial function with innate immunity, metabolism, and cellular stress responses.
Localization Studies: Mitochondrial localization of NLRX1 has been rigorously demonstrated using immunogold electron microscopy, cellular fractionation, and immunofluorescence co-localization with mitochondrial markers (TOMM20, CYTB, HSP60) (bi2024nlrx1versatilefunctions pages 1-2, bi2024nlrx1versatilefunctions pages 2-3, xiao2025theinnateimmune pages 5-7). The 2025 cardiac study employed mitochondrial sub-fractionation to definitively place NLRX1 at the inner mitochondrial membrane (xiao2025theinnateimmune pages 5-7).
Functional Assays: Mitophagy has been assessed using multiple complementary approaches including mt-Keima fluorescence (pH-sensitive mitochondrial reporter), LC3 puncta formation and co-localization with mitochondria, mitochondrial DNA/nuclear DNA ratio measurements, and transmission electron microscopy visualization of mitochondria within autophagosomes (bi2024nlrx1versatilefunctions pages 1-2, zhang2026cytosolicacetylcoenzymea pages 1-2).
Interaction Studies: Co-immunoprecipitation followed by mass spectrometry has identified key NLRX1 binding partners including FASTKD5, SLC39A7, UQCRC2, MAVS, and mTOR complex components (song2024thenlrx1slc39a7complex pages 1-2, xiao2025theinnateimmune pages 5-7, chou2022impactofintracellular pages 7-8).
In Vivo Models: NLRX1 function has been examined in multiple knockout mouse models across diverse disease contexts including: experimental autoimmune encephalomyelitis (multiple sclerosis model), cardiac ischemia-reperfusion injury, intervertebral disc degeneration, viral infections, and metabolic syndrome (song2024thenlrx1slc39a7complex pages 1-2, xiao2025theinnateimmune pages 5-7, pickering2021nlrinexile pages 9-11, chou2022impactofintracellular pages 7-8). Additionally, pig models of cardiac injury have confirmed NLRX1 downregulation following ischemia-reperfusion (xiao2025theinnateimmune pages 5-7).
Crystallography: The C-terminal LRR domain of NLRX1 (residues 629-975) has been crystallized and its structure deposited in the Protein Data Bank (PDB: 3UN9) (jewell2024insightsintothe pages 1-2). This structure has been essential for understanding ligand binding and protein-protein interactions.
AlphaFold2 Modeling: Full-length NLRX1 has been modeled using AlphaFold2, revealing a stable centrosymmetric homo-hexameric structure characteristic of AAA+ ATPases (jewell2024insightsintothe pages 1-2). These models have identified previously uncharacterized features including an RNA-binding pocket formed by N-terminal helices surrounding the hexamer center, and the acetyl-CoA binding site in the LRR domain (jewell2024insightsintothe pages 1-2, zhang2026cytosolicacetylcoenzymea pages 1-2).
Mutagenesis Studies: Domain mapping experiments have identified functional regions: the LRR domain is required for MAVS and STING interactions, metabolite binding, and IKK inhibition; the NACHT domain mediates ATPase activity and oligomerization; and the N-terminal region (beyond the MTS) contains the newly discovered RNA-binding pocket (jewell2024insightsintothe pages 1-2).
NLRX1 has emerged as a potential therapeutic target in multiple disease contexts:
Neuroinflammatory Diseases: NLRX1 protects against experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. Nlrx1−/− mice exhibit worse clinical outcomes with increased T cell infiltration and microglial activation (pickering2021nlrinexile pages 9-11). Rare NLRX1 mutations (including p.Glu192Ter truncation) have been identified in MS patients, linking genetic variants to disease susceptibility (pickering2021nlrinexile pages 1-4, pickering2021nlrinexile pages 9-11).
Cardiovascular Disease: NLRX1 provides cardioprotection during ischemia-reperfusion injury through mTOR/RISK pathway activation and mPTP regulation. NLRX1 deletion increases infarct size and cardiac dysfunction in mouse models (xiao2025theinnateimmune pages 5-7).
Metabolic Disorders: NLRX1 deficiency protects against diet-induced metabolic syndrome, NAFLD, and pancreatic dysfunction, suggesting NLRX1 inhibition could be therapeutic for metabolic disease (chou2022impactofintracellular pages 7-8).
Intervertebral Disc Degeneration: Loss of NLRX1 correlates with disc degeneration and cellular senescence. Restoration of NLRX1 function using genetic overexpression or the pharmacological agonist NX-13 shows therapeutic potential (song2024thenlrx1slc39a7complex pages 1-2).
Recent advances have substantially refined our understanding of NLRX1:
Unified Mitophagy Model (2024): The 2024 review by Bi et al. proposes that mitophagy regulation represents the overarching, unifying function of NLRX1, with other roles (immune regulation, metabolism) serving this primary quality control function (bi2024nlrx1versatilefunctions pages 1-2).
Metabolite Sensing (2026): The discovery that cytosolic AcCoA directly binds NLRX1 to control mitophagy represents a paradigm shift, establishing NLRX1 as a bona fide metabolic sensor linking nutritional status to mitochondrial homeostasis (zhang2026cytosolicacetylcoenzymea pages 1-2).
mPTP Regulation (2025): The identification of NLRX1 as essential for mPTP function opens new avenues for understanding cardioprotection and mitochondrial physiology (xiao2025theinnateimmune pages 5-7).
Therapeutic Development: Small molecule NLRX1 agonists (NX-13, NX-64-3) are in preclinical/clinical development for inflammatory and degenerative diseases (jewell2024insightsintothe pages 1-2, song2024thenlrx1slc39a7complex pages 1-2).
NLRX1 (UniProt Q86UT6) is a multifunctional regulatory protein that serves as a critical nexus linking mitochondrial function, innate immunity, and cellular metabolism. Its unique mitochondrial localization enables it to function as a sentinel for mitochondrial health, coordinating appropriate cellular responses through mitophagy, metabolic reprogramming, and inflammatory signaling modulation. The protein operates through direct interactions with key signaling molecules including MAVS, STING, LC3, FASTKD5, SLC39A7, and metabolites such as acetyl-CoA. Recent structural and functional studies from 2023-2025 have substantially advanced our molecular understanding, revealing NLRX1 as a sophisticated regulator whose therapeutic targeting holds promise for treating inflammatory, metabolic, and neurodegenerative diseases.
References
(bi2024nlrx1versatilefunctions pages 1-2): Paul Y. Bi, Samuel A. Killackey, Linus Schweizer, and Stephen E. Girardin. Nlrx1: versatile functions of a mitochondrial nlr protein that controls mitophagy. Feb 2024. URL: https://doi.org/10.1016/j.bj.2023.100635, doi:10.1016/j.bj.2023.100635. This article has 26 citations.
(pickering2021nlrinexile pages 1-4): Robert J. Pickering and Lee M. Booty. Nlr in exile: emerging roles of nlrx1 in immunity and human disease. Immunology, 162:268-280, Dec 2021. URL: https://doi.org/10.1111/imm.13291, doi:10.1111/imm.13291. This article has 53 citations and is from a peer-reviewed journal.
(chou2023thenlrgene pages 1-3): Wei-Chun Chou, Sushmita Jha, Michael W. Linhoff, and Jenny P.-Y. Ting. The nlr gene family: from discovery to present day. Nature Reviews Immunology, 23:635-654, Mar 2023. URL: https://doi.org/10.1038/s41577-023-00849-x, doi:10.1038/s41577-023-00849-x. This article has 220 citations and is from a highest quality peer-reviewed journal.
(fekete2021focusingonthe pages 1-2): Tünde Fekete, Dóra Bencze, Eduárd Bíró, Szilvia Benkő, and Kitti Pázmándi. Focusing on the cell type specific regulatory actions of nlrx1. International Journal of Molecular Sciences, 22:1316, Jan 2021. URL: https://doi.org/10.3390/ijms22031316, doi:10.3390/ijms22031316. This article has 38 citations.
(bi2024nlrx1versatilefunctions pages 2-3): Paul Y. Bi, Samuel A. Killackey, Linus Schweizer, and Stephen E. Girardin. Nlrx1: versatile functions of a mitochondrial nlr protein that controls mitophagy. Feb 2024. URL: https://doi.org/10.1016/j.bj.2023.100635, doi:10.1016/j.bj.2023.100635. This article has 26 citations.
(jewell2024insightsintothe pages 1-2): Shannon Jewell, Thanh Binh Nguyen, David B. Ascher, and Avril A.B. Robertson. Insights into the structure of nlr family member x1: paving the way for innovative drug discovery. Dec 2024. URL: https://doi.org/10.1016/j.csbj.2024.09.013, doi:10.1016/j.csbj.2024.09.013. This article has 2 citations and is from a peer-reviewed journal.
(zhang2026cytosolicacetylcoenzymea pages 1-2): Yifan Zhang, Xiao-tong Shen, Yuan Shen, Chao Wang, Chengping Yu, Jiangxue Han, Siyi Cao, Lin Qian, Miaolian Ma, Shijing Huang, Wenyu Wen, Miao Yin, and Qun-Ying Lei. Cytosolic acetyl-coenzyme a is a signalling metabolite to control mitophagy. Nature, 649(8098):1022-1031, Nov 2026. URL: https://doi.org/10.1038/s41586-025-09745-x, doi:10.1038/s41586-025-09745-x. This article has 23 citations and is from a highest quality peer-reviewed journal.
(xiao2025theinnateimmune pages 2-5): Y. Xiao, X. Hu, C. F. Rudolphi, E. E. Nollet, R. Nederlof, Q. Wang, D. Bakker, Panagiota Efstathia Nikolaou, J. C. Knol, R. R. Goeij-de Haas, A. A. Henneman, T. V. Pham, C. R. Jimenez, A. E. Grootemaat, N. N. van der Wel, S. E. Girardin, N. Kaludercic, J. van der Velden, Z. Onódi, P. Leszek, Z. V. Varga, P. Ferdinandy, B. Preckel, N. C. Weber, M. W. Hollmann, F. Di Lisa, and C. J. Zuurbier. The innate immune receptor nlrx1 is a novel required modulator for mptp opening: implications for cardioprotection. Basic Research in Cardiology, 120:707-725, Jun 2025. URL: https://doi.org/10.1007/s00395-025-01124-x, doi:10.1007/s00395-025-01124-x. This article has 8 citations and is from a domain leading peer-reviewed journal.
(xiao2025theinnateimmune pages 5-7): Y. Xiao, X. Hu, C. F. Rudolphi, E. E. Nollet, R. Nederlof, Q. Wang, D. Bakker, Panagiota Efstathia Nikolaou, J. C. Knol, R. R. Goeij-de Haas, A. A. Henneman, T. V. Pham, C. R. Jimenez, A. E. Grootemaat, N. N. van der Wel, S. E. Girardin, N. Kaludercic, J. van der Velden, Z. Onódi, P. Leszek, Z. V. Varga, P. Ferdinandy, B. Preckel, N. C. Weber, M. W. Hollmann, F. Di Lisa, and C. J. Zuurbier. The innate immune receptor nlrx1 is a novel required modulator for mptp opening: implications for cardioprotection. Basic Research in Cardiology, 120:707-725, Jun 2025. URL: https://doi.org/10.1007/s00395-025-01124-x, doi:10.1007/s00395-025-01124-x. This article has 8 citations and is from a domain leading peer-reviewed journal.
(chou2022impactofintracellular pages 7-8): Wei-Chun Chou, Elena Rampanelli, Xin Li, and Jenny P.-Y. Ting. Impact of intracellular innate immune receptors on immunometabolism. Cellular and Molecular Immunology, 19:337-351, Oct 2022. URL: https://doi.org/10.1038/s41423-021-00780-y, doi:10.1038/s41423-021-00780-y. This article has 173 citations and is from a peer-reviewed journal.
(song2024thenlrx1slc39a7complex pages 1-2): Yu Song, Huaizhen Liang, Gaocai Li, Liang Ma, Dingchao Zhu, Weifeng Zhang, Bide Tong, Shuai Li, Yong Gao, Xinghuo Wu, Yukun Zhang, Xiaobo Feng, Kun Wang, and Cao Yang. The nlrx1-slc39a7 complex orchestrates mitochondrial dynamics and mitophagy to rejuvenate intervertebral disc by modulating mitochondrial zn 2+ trafficking. Nov 2024. URL: https://doi.org/10.1080/15548627.2023.2274205, doi:10.1080/15548627.2023.2274205. This article has 72 citations and is from a domain leading peer-reviewed journal.
(pickering2021nlrinexile pages 9-11): Robert J. Pickering and Lee M. Booty. Nlr in exile: emerging roles of nlrx1 in immunity and human disease. Immunology, 162:268-280, Dec 2021. URL: https://doi.org/10.1111/imm.13291, doi:10.1111/imm.13291. This article has 53 citations and is from a peer-reviewed journal.